O	0	3	The
O	4	17	effectiveness
O	18	20	of
O	21	22	a
O	23	31	clinical
O	32	35	and
O	36	40	home
O	40	41	-
O	41	46	based
B-intervention	47	55	physical
I-intervention	56	64	activity
I-intervention	65	72	program
I-intervention	73	76	and
I-intervention	77	83	simple
I-intervention	84	93	lymphatic
I-intervention	94	102	drainage
O	103	105	in
O	106	109	the
O	110	120	prevention
O	121	123	of
B-condition	124	130	breast
I-condition	131	137	cancer
I-condition	137	138	-
I-condition	138	145	related
I-condition	146	156	lymphedema
O	156	157	:
O	158	159	A
O	160	171	prospective
O	172	182	randomized
O	183	193	controlled
O	194	199	study
O	199	200	.

O	201	203	To
O	204	215	investigate
O	216	219	the
O	220	233	effectiveness
O	234	236	of
O	237	238	a
O	239	247	clinical
O	248	251	and
O	252	256	home
O	256	257	-
O	257	262	based
O	262	263	,
O	264	269	nurse
O	269	270	-
O	270	273	led
O	274	282	physical
O	283	291	activity
O	292	299	program
O	300	301	(
O	301	304	PAP
O	304	305	)
O	306	309	and
O	310	316	simple
O	317	326	lymphatic
O	327	335	drainage
O	336	337	(
O	337	340	SLD
O	340	341	)
O	342	344	in
O	345	348	the
O	349	359	prevention
O	360	362	of
O	363	369	breast
O	370	376	cancer
O	376	377	-
O	377	384	related
O	385	395	lymphedema
O	395	396	.

O	397	398	A
O	399	404	total
O	405	407	of
B-total-participants	408	410	52
O	411	417	breast
O	418	424	cancer
O	425	433	patients
O	434	438	were
O	439	449	randomized
O	450	452	to
O	453	459	either
O	460	461	a
O	462	465	PAP
O	466	469	and
O	470	473	SLD
O	474	481	program
O	482	483	(
O	483	484	n
O	485	486	=
B-intervention-participants	487	489	25
O	489	490	)
O	491	493	or
O	494	495	a
B-control	496	503	control
I-control	504	509	group
O	510	511	(
O	511	512	n
O	513	514	=
B-control-participants	515	517	27
O	517	518	)
O	518	519	.

O	520	528	Patients
O	529	531	in
O	532	536	both
O	537	543	groups
O	544	548	were
O	549	553	also
O	554	562	provided
O	563	571	training
O	572	575	for
O	576	586	lymphedema
O	586	587	.

O	588	591	The
O	592	595	PAP
O	596	599	and
O	600	603	SLD
O	604	608	were
O	609	621	administered
O	622	629	through
O	630	634	home
O	635	641	visits
O	642	644	by
O	645	648	the
O	649	662	investigators
O	662	663	,
O	664	669	twice
O	670	671	a
O	672	676	week
O	677	680	for
O	681	684	six
O	685	690	weeks
O	690	691	,
O	692	694	in
O	695	698	the
O	699	711	intervention
O	712	717	group
O	717	718	.

O	719	722	The
O	723	730	control
O	731	736	group
O	737	740	did
O	741	744	not
O	745	752	undergo
O	753	765	intervention
O	765	766	.

O	767	770	The
O	771	784	circumference
O	785	787	of
O	788	791	the
O	792	797	upper
O	798	807	extremity
O	807	808	,
O	809	816	symptom
O	817	825	severity
O	825	826	,
O	827	830	and
O	831	839	physical
O	840	848	function
O	849	853	were
O	854	862	measured
O	863	865	in
O	866	870	both
O	871	877	groups
O	877	878	.

O	879	882	The
B-outcome	883	888	upper
I-outcome	889	898	extremity
I-outcome	899	912	circumference
O	913	922	increased
O	923	925	by
O	926	931	about
O	932	935	two
O	936	941	times
O	942	946	from
O	947	950	the
O	951	959	baseline
O	959	960	,
O	961	963	in
O	964	967	the
O	968	975	control
O	976	981	group
O	981	982	,
O	983	993	especially
O	994	996	in
O	997	1000	the
O	1001	1006	sixth
O	1007	1011	week
O	1012	1013	(
O	1013	1014	p
O	1015	1016	<
O	1017	1018	0
O	1018	1019	.
O	1019	1021	05
O	1021	1022	)
O	1022	1023	.

B-outcome	1024	1034	Lymphedema
I-outcome	1034	1035	-
I-outcome	1035	1042	related
I-outcome	1043	1050	symptom
I-outcome	1051	1059	severity
I-outcome	1060	1066	scores
O	1067	1071	were
O	1072	1077	found
O	1078	1080	to
O	1081	1089	decrease
O	1090	1103	significantly
O	1104	1106	in
O	1107	1110	the
O	1111	1123	intervention
O	1124	1129	group
O	1129	1130	,
O	1131	1139	compared
O	1140	1142	to
O	1143	1148	those
O	1149	1151	at
O	1152	1155	the
O	1156	1164	baseline
O	1165	1166	(
O	1166	1167	p
O	1168	1169	<
O	1170	1171	0
O	1171	1172	.
O	1172	1174	05
O	1174	1175	)
O	1175	1176	.

O	1177	1179	It
O	1180	1183	was
O	1184	1195	recommended
O	1196	1200	that
O	1201	1204	PAP
O	1205	1208	and
O	1209	1212	SLD
O	1212	1213	,
O	1214	1218	with
O	1219	1220	a
O	1221	1227	follow
O	1227	1228	-
O	1228	1230	up
O	1231	1238	program
O	1238	1239	,
O	1240	1242	be
O	1243	1247	used
O	1248	1251	for
O	1252	1260	patients
O	1261	1264	who
O	1265	1272	planned
O	1273	1275	to
O	1276	1283	undergo
O	1284	1290	breast
O	1291	1297	cancer
O	1298	1305	surgery
O	1305	1306	,
O	1307	1315	starting
O	1316	1320	from
O	1321	1327	before
O	1328	1335	surgery
O	1336	1339	and
O	1340	1350	continuing
O	1351	1356	until
O	1357	1362	after
O	1362	1363	,
O	1364	1366	to
O	1367	1374	prevent
O	1375	1381	breast
O	1382	1388	cancer
O	1388	1389	-
O	1389	1396	related
O	1397	1407	lymphedema
O	1407	1408	.
